IRIS - Res&Arch Institutional Research Information System - Research & Archive

BORDONI, Martina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.170
AS - Asia 1.005
EU - Europa 673
SA - Sud America 121
Continente sconosciuto - Info sul continente non disponibili 82
AF - Africa 20
OC - Oceania 5
Totale 3.076
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.115
SG - Singapore 434
IT - Italia 226
CN - Cina 148
HK - Hong Kong 113
RU - Federazione Russa 100
IE - Irlanda 94
VN - Vietnam 92
BR - Brasile 88
BD - Bangladesh 69
DE - Germania 62
FR - Francia 45
KR - Corea 38
CA - Canada 32
IN - India 24
FI - Finlandia 21
NL - Olanda 19
GB - Regno Unito 18
PL - Polonia 16
AT - Austria 15
MX - Messico 14
IQ - Iraq 13
TR - Turchia 13
BE - Belgio 10
JP - Giappone 10
AR - Argentina 9
ES - Italia 9
PK - Pakistan 9
SE - Svezia 9
UA - Ucraina 9
ID - Indonesia 8
ZA - Sudafrica 7
EC - Ecuador 6
SA - Arabia Saudita 6
CO - Colombia 5
VE - Venezuela 4
AU - Australia 3
BO - Bolivia 3
CR - Costa Rica 3
KW - Kuwait 3
MA - Marocco 3
RO - Romania 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GR - Grecia 2
IL - Israele 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PY - Paraguay 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AI - Anguilla 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CH - Svizzera 1
CL - Cile 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
LK - Sri Lanka 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
YT - Mayotte 1
Totale 2.994
Salva come PNG Salva come JPEG
Città #
Singapore 347
San Jose 135
Chandler 130
Ashburn 123
Hong Kong 113
Dublin 90
Perugia 83
Santa Clara 49
Los Angeles 40
Moscow 40
Seoul 38
Munich 36
Boardman 35
Ann Arbor 34
New York 33
Beijing 29
Lauterbourg 29
San Mateo 28
Dong Ket 21
Hanoi 18
Piscataway 18
Ho Chi Minh City 17
Medford 16
Milan 16
Princeton 16
Altamura 15
Warsaw 15
Brooklyn 13
Turku 12
The Dalles 11
Toronto 11
Wilmington 11
Amsterdam 10
Brussels 10
Dallas 10
Lawrence 10
Rome 10
Tokyo 10
Buffalo 9
Hefei 9
Redwood City 9
São Paulo 9
Montreal 8
Baghdad 7
Denver 7
Nuremberg 7
Vicenza 7
Vienna 7
Chicago 6
Florence 6
Frankfurt am Main 6
Helsinki 6
Naples 6
Orem 6
Stockholm 6
Andover 5
Council Bluffs 5
Houston 5
Mexico City 5
Phoenix 5
Poplar 5
Saint Petersburg 5
San Francisco 5
Seattle 5
Bologna 4
Den Haag 4
Des Moines 4
Gualdo Cattaneo 4
Miami 4
Querétaro 4
Ankara 3
Cambridge 3
Can Tho 3
Chennai 3
Hải Dương 3
Jeddah 3
Lahore 3
Lappeenranta 3
Manchester 3
New Delhi 3
Quito 3
San José 3
Secaucus 3
Shanghai 3
Sydney 3
Turin 3
Vancouver 3
Zhengzhou 3
Abidjan 2
As Sālimīyah 2
Athens 2
Atlanta 2
Barcelona 2
Calgary 2
Cape Town 2
Castello di Cisterna 2
Catania 2
Cedar Knolls 2
Charlotte 2
Cochabamba 2
Totale 1.950
Salva come PNG Salva come JPEG
Nome #
The aryl hydrocarbon receptor (AhR) mediates the counter-regulatory effects of pelargonidins in models of inflammation and metabolic dysfunctions 117
Identification of Cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1 114
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction 111
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases 106
Analysis of Oral and Gut Microbiota Composition in Children with Dental Caries by NGS Approaches 105
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease 105
Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation 105
The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity 102
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling 102
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy 98
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis 97
GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation 93
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease 93
Tu1546 – Gpbar1 is a Modulator of Liver Immunity and Its Agonism Reverses Acetaminophen-Induced Hepatotoxicity by Modulating Recruitment of Liver Macrophages 92
Mo2014 – Comparative Effects of Bar502, a Dual Fxr and Gpbar1 Agonist, Obeticholic Acid and Ursodeoxycholic Acid in a Rodent Model of Nash 91
Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis 89
Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury 89
Sa1518 – Mechanism of Acute Liver Decompensation Caused by Obeticholic Acid in Cholestasis is Fxr Dependent 88
GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis 88
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH 87
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer 85
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease 85
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice 84
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 82
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling 78
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 77
Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis 77
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation 75
Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis 71
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis 70
Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism 69
Modeling Inflammatory Bowel Disease by Intestinal Organoids 66
Organoids as ex vivo culture system to investigate infection-host interaction in gastric pre-carcinogenesis 57
Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4 −/− mice 55
Dysregulated Lipid and Protein Networks in Osteochondrosis 38
Tumor-Derived LIF Promotes GDF15-Driven Cachexia and Adverse Outcomes in Gastric Cancer 30
The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy 5
Totale 3.076
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.316
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.316
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022125 0 23 1 5 1 1 13 24 2 16 13 26
2022/2023388 27 60 4 32 39 43 0 17 143 1 14 8
2023/2024195 8 17 3 5 12 1 51 26 17 8 26 21
2024/2025646 7 41 29 40 41 60 51 69 133 29 93 53
2025/20261.507 93 98 74 202 220 118 212 69 139 133 71 78
2026/202782 39 43 0 0 0 0 0 0 0 0 0 0
Totale 3.076